

PHARMACY FACTS

Program Updates from Louisiana Medicaid

November 17, 2021

Brand Over Generic List: [PHARMACISTS – adjust your inventory accordingly](#)

On November 3, 2021, LDH held a virtual Pharmaceutical & Therapeutics (P&T) Committee review via Zoom. LDH's legal department authorized Pharmacy staff to host a review in lieu of an actual meeting due to the constraints of COVID-19 and the current public meeting laws. Since this was a virtual review, it was conducted without the P&T members voting. However, feedback from committee members, the public and drug manufacturers was allowed and taken into consideration.

In addition, the Pharmacy Advisory Council (PAC) members reviewed the Brand over Generic list and provided feedback as well. There are times when brand products are preferred over generics because the net price to the state is less expensive after rebate. After considering the financial and clinical impacts, as well as the feedback on the proposed recommendations, the Brand over Generic List will be as follows effective January 1, 2022:

Brand Over Generic List for Fall 2021 Effective January 1, 2022 (highlight is new to the list)	Spring/Fall
ADDERALL XR	Fall
ADVAIR DISKUS (INHALATION)	Fall
AFINITOR (ORAL)	Fall
ALPHAGAN P 0.15% (OPHTHALMIC)	Fall
AMITIZA (ORAL)	Spring
APRISO (ORAL)	Spring
BANZEL TABLET AND SUSPENSION	Fall
BETHKIS (INHALATION)	Spring
CARBATROL (ORAL)	Fall
CATAPRES-TTS (TRANSDERM)	Fall
CIPRODEX (OTIC)	Fall
COPAXONE 20 MG/ML (SUBCUTANE.)	Spring
DEPAKOTE SPRINKLE (ORAL)	Fall
DIASTAT RECTAL	Fall
ELIDEL (TOPICAL)	Fall
FELBATOL TABLET (ORAL)	Fall
IMITREX (NASAL)	Spring
NATROBA (TOPICAL)	Spring
NEXIUM SUSPENSION (ORAL)	Spring
PROTONIX SUSPENSION (ORAL)	Spring

PHARMACY FACTS

Program Updates from Louisiana Medicaid

RAPAMUNE SOLUTION and TABLET (ORAL)	Spring
REVELA TABLET (ORAL)	Spring
RETIN-A CREAM (TOPICAL)	Spring
SABRIL TABLET and POWDER PACK (ORAL)	Fall
SAPHRIS	Fall
SUBOXONE FILM (SUBLINGUAL)	Spring
SUTENT	Fall
SYMBICORT (INHALATION)	Fall
TECFIDERA and TECFIDERA STARTER PACK (ORAL)	Spring
TEGRETOL XR (ORAL)	Fall
TOBRADEX SUSPENSION (OPHTHALMIC)	Fall
TRAVATAN Z (OPHTHALMIC)	Fall
TRILEPTAL SUSPENSION (ORAL)	Fall
ZAVESCA	Fall

	Brand Over Generic Products Removed - Fall 2021	Notes
1	FOCALIN XR (ORAL)	Generic will be preferred

Preferred Drug List (PDL) Updates

The new PDL will be implemented on January 1, 2022.

There are two new therapeutic classes added to the PDL. Those classes include:

- Immunomodulators, Lupus.
- Ophthalmics, Cystinosis.

Chantix Brand Not Available, Only PAR Generic Company Covered

We are aware of a manufacturer issue and shortage with the brand Chantix, which is the Medicaid preferred product. During the shortage, PAs should be approved for the generic varenicline when the unavailability of Chantix is documented in the PA submission. **PAR pharmaceuticals** is the only manufacturer of varenicline that is currently covered by Medicaid due to rebate eligibility.